$1.36
8.09%
Downside
Day's Volatility :13.19%
Upside
5.56%
14.71%
Downside
52 Weeks Volatility :61.84%
Upside
55.26%
Period | I-mab | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -22.78% | 6.5% | 0.0% |
6 Months | -22.78% | 7.1% | 0.0% |
1 Year | -53.51% | 9.8% | 0.0% |
3 Years | -97.79% | 14.2% | -20.2% |
Market Capitalization | 114.0M |
Book Value | $21.29 |
Earnings Per Share (EPS) | -2.42 |
Wall Street Target Price | 26.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -7062.8% |
Return On Assets TTM | -23.11% |
Return On Equity TTM | -63.34% |
Revenue TTM | 27.6M |
Revenue Per Share TTM | 0.33 |
Quarterly Revenue Growth YOY | -62.1% |
Gross Profit TTM | 41.6M |
EBITDA | -1.2B |
Diluted Eps TTM | -2.42 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 1811.76%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 7.8M | ↑ 365.39% |
Net Income | -58.6M | ↑ 35.07% |
Net Profit Margin | -749.02% | ↑ 1831.8% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.3M | ↓ 44.22% |
Net Income | -208.3M | ↑ 261.15% |
Net Profit Margin | -4.8K% | ↓ 4100.46% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 236.5M | ↑ 5042.23% |
Net Income | 72.2M | ↓ 132.37% |
Net Profit Margin | 30.53% | ↑ 4880.01% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 13.8M | ↓ 94.29% |
Net Income | -365.9M | ↓ 595.11% |
Net Profit Margin | -2.6K% | ↓ 2679.23% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | -32.1M | ↓ 351.7% |
Net Income | -349.7M | ↑ 3.44% |
Net Profit Margin | 1.1K% | ↑ 3737.25% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 27.6M | ↓ 112.48% |
Net Income | -1.5B | ↓ 39.23% |
Net Profit Margin | -5.3K% | ↓ 6390.58% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | -238.4M | - |
Net Income | -303.0M | - |
Net Profit Margin | 127.12% | - |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 8.0M | - |
Net Income | -161.5M | - |
Net Profit Margin | -2.0K% | - |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | -256.8M | ↓ 22147.83% |
Net Income | -433.4M | ↑ 1743.3% |
Net Profit Margin | 168.77% | ↑ 2187.47% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.8M | ↓ 100.16% |
Net Income | -111.5M | ↓ 96.26% |
Net Profit Margin | -3.9K% | ↓ 4100.57% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.1M | ↓ 61.08% |
Net Income | -95.7M | ↓ 14.14% |
Net Profit Margin | -8.7K% | ↓ 4741.35% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 345.5M | ↑ 131.72% |
Total Liabilities | 484.4M | ↑ 151.37% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 248.7M | ↓ 26.87% |
Total Liabilities | 540.0M | ↑ 13.25% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 971.1M | ↑ 264.52% |
Total Liabilities | 108.3M | ↓ 81.27% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 883.4M | ↓ 11.12% |
Total Liabilities | 163.5M | ↑ 47.41% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 590.7M | ↓ 27.64% |
Total Liabilities | 154.5M | ↑ 2.28% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.6B | ↓ 35.86% |
Total Liabilities | 894.8M | ↓ 16.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 590.7M | ↓ 18.39% |
Total Liabilities | 154.5M | ↑ 9.21% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 511.1M | ↓ 13.8% |
Total Liabilities | 155.0M | ↓ 0.04% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 484.2M | ↑ 0.0% |
Total Liabilities | 146.8M | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↓ 25.59% |
Total Liabilities | 894.8M | ↓ 15.97% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 0.0% |
Total Liabilities | 894.8M | ↑ 0.0% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 0.0% |
Total Liabilities | 894.8M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -40.8M | ↑ 11.32% |
Investing Cash Flow | 1.4M | ↓ 106.03% |
Financing Cash Flow | 215.2M | ↑ 95.06% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -124.3M | ↑ 209.22% |
Investing Cash Flow | 30.4M | ↑ 2136.44% |
Financing Cash Flow | 21.9M | ↓ 89.68% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 66.5M | ↓ 149.95% |
Investing Cash Flow | -31.0M | ↓ 195.03% |
Financing Cash Flow | 527.5M | ↑ 2152.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -152.7M | ↓ 324.44% |
Investing Cash Flow | -114.1M | ↑ 260.18% |
Financing Cash Flow | 93.2M | ↓ 82.74% |
Q3 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -41.1M | ↑ 19.84% |
Investing Cash Flow | -26.8M | ↓ 9.32% |
Financing Cash Flow | 8.4M | ↓ 77.85% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -41.6M | ↑ 0.0% |
Investing Cash Flow | -27.1M | ↑ 0.0% |
Financing Cash Flow | 8.4M | ↑ 0.0% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -313.5M | ↑ 650.03% |
Investing Cash Flow | 39.3M | ↓ 244.39% |
Financing Cash Flow | 8.5M | ↑ 0.0% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -42.6M | ↓ 85.64% |
Investing Cash Flow | 37.3M | ↑ 0.0% |
Financing Cash Flow | 2.6M | ↓ 67.15% |
Sell
Neutral
Buy
I-mab is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() I-mab | -18.48% | -22.78% | -53.51% | -97.79% | -98.26% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() I-mab | NA | NA | NA | 0.0 | -0.63 | -0.23 | NA | 21.29 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() I-mab | Buy | $114.0M | -98.26% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on I-mab
Revenue is down for the last 2 quarters, 2.83M → 1.10M (in $), with an average decrease of 61.1% per quarter
Netprofit is up for the last 3 quarters, -2.97B → -95.73M (in $), with an average increase of 1293.5% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 115.1%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 284.3%
Hillhouse Capital Advisors, Ltd.
Caligan Partners LP
Two Sigma Advisers, LLC
Two Sigma Investments LLC
Temasek Holdings Ltd.
GSA Capital Partners LLP
i-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm
Organization | I-mab |
Employees | 220 |
CEO | Mr. Raj Kannan |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.36
-2.16%
Keyarch Acquisition Corp
$1.36
-2.16%
Connexa Sports Technologies Inc
$1.36
-2.16%
Us Value Etf
$1.36
-2.16%
First Wave Biopharma Inc
$1.36
-2.16%
Global X Msci Next Emerging
$1.36
-2.16%
Fat Projects Acquisition Corp
$1.36
-2.16%
Capital Link Global Fintech
$1.36
-2.16%
Applied Uv Inc
$1.36
-2.16%